OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!

XClose

Research News

BRCA Mutations Confer Risk, Even in Absence of Family History

(October 15, 2015)  According to a Japanese study published in Cancer, BRCA1/2 gene mutations may be associated with an inherited risk of ovarian cancer regardless of family history. The researchers examined 95 women with ovarian cancer who were treated from 2013 to 2015.  BRCA1/2 gene mutation... 

Most Women Getting BRCA Test not Getting Genetic Counseling

(October 7, 2015) A report published in JAMA Oncology shows that most commercially insured women who underwent BRCA genetic testing did not receive genetic counseling by trained genetics professionals.  Lack of clinician recommendation was the most commonly reported reason why they didn’t receive... 

Hormone Replacement Therapy Beneficial to Ovarian Cancer Patients

(October 1, 2015) A new study published in the Journal of Clinical Oncology shows that women with the most common type of ovarian cancer can safely take hormone replacement therapy (HRT), and it could have a beneficial effect on their survival. The 24-year, phase III international trial provides the... 

Small Trial Shows Promising Results for Nivolumab in Ovarian Cancer

(September 21, 2015) A small study found that treatment with the anti-PD-1 immunotherapy nivolumab was able to produce complete responses in patients with advanced platinum-resistant ovarian cancer. The phase II study of 20 patients had an overall response rate of 15% (3 responders); an additional 6... 

Q&A with OCRF Grantee Kris Wood, PhD

Kris Wood, PhD Q&A with Kris Wood, PhD Duke University 2014 Liz Tilberis Award   OCRF: Tell me about yourself. Kris Wood: I grew up in Georgetown, KY, a rural town in the central part of the state. My family lived in a house on my grandfather’s farm, which was a wonderful place to grow up–... 

OCRF Research Shows Heart Medication Prolongs Life in Ovarian Cancer Patients

(August 26, 2015) Women with epithelial ovarian cancer who happened to be taking nonselective beta-blockers for hypertension survived longer than those who were not taking the drugs, according to a large multicenter retrospective study.  The study was funded in part by an OCRF grant to Dr. Anil Sood... 

Multi-gene Testing for Ovarian Cancer Risk is Clinically Useful

(August 21, 2015) A study published online in JAMA Oncology this month shows that screening women with a suspected risk of hereditary breast or ovarian cancer with a multigene panel (which looks for mutations in many genes), identifies more people with cancer risk related gene mutations than screening... 

RAD51 Mutations Confer Moderate Risk of Ovarian Cancer

(August 19, 2015)  Deleterious mutations in RAD51C and RAD51D genes are associated with increased risk of epithelial ovarian cancer (EOC), according to a study published online Aug. 10 in the Journal of Clinical Oncology. Honglin Song, PhD, from the University of Cambridge in the United Kingdom, and... 

OCRF Research Finds Combination Immunotherapy Promising

OCRF Grantee Michael Goldberg, PhD (August 19, 2015) Whereas chemotherapy kills cancer cells only while it is being administered, immunotherapy can lead to an adaptive immune response that persists long after treatment is ceased. By simple analogy, whereas aspirin provides temporary pain relief, a polio... 

Ovarian Cancer Survival Rates Higher Than Thought

(August 17, 2015) A study from the University of California, Davis found that one-third of women with ovarian cancer survive at least 10 years after diagnosis. The study, published in the Journal of Obstetrics and Gynecology, linked high survival rates with younger ages, early stages, and tumor type...